Physician profile
Eric A Dorn
NPI 1457529299
$3,533.43
in general payments reported to CMS, 2019-2025
27 companies · $767 in 2025
The $767 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $111 · 2021: $484 · 2022: $295 · 2023: $778 · 2024: $695 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $686.86 | 2019-2024 | Jornay Pm |
| Corium, LLC | $390.50 | 2022-2025 | Azstarys |
| Pfizer INC. | $292.85 | 2019-2025 | |
| Smith+Nephew, INC. | $271.34 | 2025 | Tula |
| Tris Pharma INC | $236.51 | 2021-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $182.16 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $174.27 | 2021-2025 | Doc Band |
| Neos Therapeutics, Lp | $158.82 | 2023-2025 | Cotempla Xr-Odt |
| Kaleo, INC. | $157.95 | 2019-2023 | Auvi-Q |
| Adlon Therapeutics L.P. | $156.92 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $140.28 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $139.60 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $86.54 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $67.28 | 2021-2022 | |
| Alk-Abello, INC | $66.65 | 2025 | Neffy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $50.43 | 2025 | |
| Vertical Pharmaceuticals, LLC | $45.76 | 2019-2024 | Relexxii |
| Genentech USA, INC. | $39.85 | 2019-2021 | |
| Cognoa, INC. | $33.47 | 2022 | |
| Glaxosmithkline, LLC. | $28.70 | 2021-2023 | Bexsero |
| Seqirus USA INC | $26.65 | 2022-2025 | Flucelvax |
| Agios Pharmaceuticals, INC. | $25.28 | 2025 | Pyrukynd |
| Biogen, INC. | $17.74 | 2023 | Spinraza |
| Azurity Pharmaceuticals, INC. | $16.67 | 2025 | Alvesco |
| Ars Pharmaceuticals Operations, INC. | $15.77 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $12.94 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.